Shares of AC Immune SA (NASDAQ:ACIU) have been given a consensus rating of “Hold” by the six brokerages that are presently covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $13.00.

ACIU has been the topic of several research analyst reports. HC Wainwright set a $8.00 price objective on AC Immune and gave the company a “buy” rating in a research note on Friday, July 12th. ValuEngine raised AC Immune from a “sell” rating to a “hold” rating in a research note on Wednesday, June 12th. Finally, BidaskClub lowered AC Immune from a “buy” rating to a “hold” rating in a research note on Wednesday, August 28th.

A number of institutional investors have recently added to or reduced their stakes in ACIU. Artisan Partners Limited Partnership acquired a new position in AC Immune during the 1st quarter worth approximately $903,000. Acadian Asset Management LLC purchased a new stake in AC Immune during the 2nd quarter worth approximately $492,000. Citadel Advisors LLC increased its holdings in AC Immune by 34.2% during the 2nd quarter. Citadel Advisors LLC now owns 166,427 shares of the company’s stock worth $924,000 after purchasing an additional 42,414 shares during the last quarter. Athanor Capital LP purchased a new stake in AC Immune during the 2nd quarter worth approximately $234,000. Finally, Private Advisors LLC purchased a new stake in AC Immune during the 1st quarter worth approximately $202,000. 26.75% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ ACIU traded down $0.05 during midday trading on Monday, hitting $5.25. The stock had a trading volume of 998,349 shares, compared to its average volume of 316,868. The company has a market capitalization of $358.08 million, a price-to-earnings ratio of -6.40 and a beta of 0.07. AC Immune has a 1-year low of $3.25 and a 1-year high of $12.50. The company has a quick ratio of 21.90, a current ratio of 21.90 and a debt-to-equity ratio of 0.01. The company has a fifty day moving average price of $5.38 and a 200 day moving average price of $5.12.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Read More: Certificate of Deposit (CD)

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.